ClinVar Miner

Submissions for variant NM_000155.4(GALT):c.253-2A>G (rs111033661)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000185912 SCV000228800 pathogenic not provided 2015-10-23 criteria provided, single submitter clinical testing
GeneDx RCV000185912 SCV000238865 pathogenic not provided 2017-04-26 criteria provided, single submitter clinical testing The c.253-2A>G splice site mutation in the GALT gene has been previously reported in Hispanic individuals with galactosemia (Yang et al., 2002). This mutation destroys the canonical splice acceptor site in intron 2, and is expected to cause abnormal gene splicing. We interpret c.253-2 A>G to be a pathogenic mutation.The variant is found in GALT panel(s).
Invitae RCV000022073 SCV000631390 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2017-02-22 criteria provided, single submitter clinical testing This sequence change affects an acceptor splice site in intron 2 of the GALT gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. Loss-of-function variants in GALT are known to be pathogenic. This variant has been observed to co-occur with a second GALT variant in multiple Hispanic individuals affected with galactosemia (PMID: 11754113, Invitae). ClinVar contains an entry for this variant (Variation ID: 25142). For these reasons, this variant has been classified as Pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV000022073 SCV000695685 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2016-06-13 criteria provided, single submitter clinical testing Variant summary: The GALT c.253-2A>G variant involves the alteration of a conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict a loss of canonical splicing acceptor site and ESEfinder predicts changes to binding motifs for splicing enhancers. This variant was found in 3/121410 control chromosomes at a frequency of 0.0000247, which does not exceed the estimated maximal expected allele frequency of a pathogenic GALT variant (0.0028868). This variant has been reported in multiple affected individuals in both homozygous and compound heterozygous status. One homozygous patient had an erythrocyte GALT activity of one-third of the normal value (Velazquez-Aragon_2008). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Research and Development, ARUP Laboratories RCV000022073 SCV000042749 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2012-12-04 no assertion criteria provided clinical testing Converted during submission to Pathogenic.
GeneReviews RCV000022073 SCV000147992 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2014-04-03 no assertion criteria provided literature only
Counsyl RCV000022073 SCV000677939 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2017-06-15 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.